Emerging drugs for the treatment of Hidradenitis Suppurativa Article

cited authors

  • Folkes, AS; Hawatmeh, FZ; Wong, A; Kerdel, FA

fiu authors


  • Introduction: Hidradenitis suppurativa (HS) is a severe, chronic inflammatory disorder that causes recurrent occlusion of hair follicles in the intertriginous regions of the skin. Mild to moderate HS has been successfully treated with oral antibiotics, topical therapy and lifestyle modifications. However, moderate to severe HS is known to be refractory to conventional treatments. Wide excision surgery is a treatment option for severe HS, but often leads to functional impairments. Additionally, recurrence is common. The proper management of moderate to severe HS continues to be a challenge to practitioners. Areas covered: A comprehensive literature search was conducted to identify published HS treatments using PubMed databases, in addition ongoing studies were sought in clinicaltrials.gov. Search terms included “hidradenitis suppurativa,” “treatment”, and “management.” Expert opinion: Although adalimumab is currently the only biologic approved by the United States Food and Drug Administration for treatment of HS, there are many studies underway involving the development of drugs with a variety of immunological targets. Those potential HS therapies in either Phase II or Phase III trials show much promise. Since HS is a complicated disease that involves both pathological and environmental factors, treating HS continues to involve a multidisciplinary approach and monotherapy tends to not be efficacious.

publication date

  • January 1, 2020

Digital Object Identifier (DOI)